{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-037025","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.674921+00:00","generated_at":"2026-05-16T14:10:59.812811+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neflamapimod slows DLB progression in Phase 2b; 89% worsening reduction in key subgroup","bullets":["Primary endpoint CDR-SB mean change 52% lower with DP Batch B vs control; 82% lower in patients without AD co-pathology.","Within-patient comparison vs placebo: 1.12 point improvement on CDR-SB (p=0.005); ADCS-CGIC improved (p=0.004).","Risk of clinical progression reduced 75%; median time to progression extended from 16 weeks to 1.5 years.","Plasma GFAP reduced median -16.0 pg/mL (p<0.0001); reduction correlated with clinical treatment response.","Company planning Phase 3 registrational trial in patients with DLB starting H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-037025","json":"https://secwatch.observer/filing/0001437749-25-037025.json","markdown":"https://secwatch.observer/filing/0001437749-25-037025.md","text":"https://secwatch.observer/filing/0001437749-25-037025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925037025/0001437749-25-037025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925037025/crvo20251205_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:10:59.812811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}